Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.55 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7287096 | 1.00 | REN (0.55) | RENCTSDF2OPRM1OPRD1 | |
| SCHEMBL2196663 | 0.93 | REN (0.49) | RENCTSDOPRM1 | |
| SCHEMBL7296864 | 0.88 | OPRM1 (0.52) | OPRM1OPRD1OPRK1 | |
| SCHEMBL7296869 | 0.88 | OPRM1 (0.52) | OPRM1OPRD1OPRK1 | |
| SCHEMBL7292591 | 0.87 | REN (0.51) | REN | |
| SCHEMBL7292596 | 0.87 | REN (0.51) | REN | |
| SCHEMBL7286971 | 0.85 | PSMB5 (0.51) | RENCTSD | |
| SCHEMBL7286963 | 0.85 | PSMB5 (0.51) | RENCTSD | |
| SCHEMBL10826524 | 0.83 | SLC6A2 (0.53) | RENOPRM1OPRD1OPRK1 | |
| SCHEMBL10777493 | 0.83 | REN (0.77) | RENCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| EP-0264106-B1 | 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use | BANYU PHARMA CO LTD (JP) | 1994-03-16 | — | — | EP | disclosed |
| US-4851387-A | RENIN INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| EP-0264106-A2 | 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | REN 2640/4885CTSD 1192/4885F2 2099/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | REN 2640/4885CTSD 1192/4885F2 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.